BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 20823098)

  • 1. Novel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets.
    Sloop KW; Willard FS; Brenner MB; Ficorilli J; Valasek K; Showalter AD; Farb TB; Cao JX; Cox AL; Michael MD; Gutierrez Sanfeliciano SM; Tebbe MJ; Coghlan MJ
    Diabetes; 2010 Dec; 59(12):3099-107. PubMed ID: 20823098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations to the third cytoplasmic domain of the glucagon-like peptide 1 (GLP-1) receptor can functionally uncouple GLP-1-stimulated insulin secretion in HIT-T15 cells.
    Salapatek AM; MacDonald PE; Gaisano HY; Wheeler MB
    Mol Endocrinol; 1999 Aug; 13(8):1305-17. PubMed ID: 10446905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
    Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
    Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice.
    Pederson RA; Satkunarajah M; McIntosh CH; Scrocchi LA; Flamez D; Schuit F; Drucker DJ; Wheeler MB
    Diabetes; 1998 Jul; 47(7):1046-52. PubMed ID: 9648827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positive Allosteric Modulation of the Glucagon-like Peptide-1 Receptor by Diverse Electrophiles.
    Bueno AB; Showalter AD; Wainscott DB; Stutsman C; Marín A; Ficorilli J; Cabrera O; Willard FS; Sloop KW
    J Biol Chem; 2016 May; 291(20):10700-15. PubMed ID: 26975372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional receptors for the insulinotropic hormone glucagon-like peptide-I(7-37) on a somatostatin secreting cell line.
    Fehmann HC; Habener JF
    FEBS Lett; 1991 Feb; 279(2):335-40. PubMed ID: 1672112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice.
    Gault VA; Bhat VK; Irwin N; Flatt PR
    J Biol Chem; 2013 Dec; 288(49):35581-91. PubMed ID: 24165127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein.
    Glaesner W; Vick AM; Millican R; Ellis B; Tschang SH; Tian Y; Bokvist K; Brenner M; Koester A; Porksen N; Etgen G; Bumol T
    Diabetes Metab Res Rev; 2010 May; 26(4):287-96. PubMed ID: 20503261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small molecule allosteric modulation of the glucagon-like Peptide-1 receptor enhances the insulinotropic effect of oxyntomodulin.
    Willard FS; Wootten D; Showalter AD; Savage EE; Ficorilli J; Farb TB; Bokvist K; Alsina-Fernandez J; Furness SG; Christopoulos A; Sexton PM; Sloop KW
    Mol Pharmacol; 2012 Dec; 82(6):1066-73. PubMed ID: 22930710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide-1(7-36)-amide confers glucose sensitivity to previously glucose-incompetent beta-cells in diabetic rats: in vivo and in vitro studies.
    Dachicourt N; Serradas P; Bailbé D; Kergoat M; Doaré L; Portha B
    J Endocrinol; 1997 Nov; 155(2):369-76. PubMed ID: 9415071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
    Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
    Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mouse pancreatic beta-cells exhibit preserved glucose competence after disruption of the glucagon-like peptide-1 receptor gene.
    Flamez D; Van Breusegem A; Scrocchi LA; Quartier E; Pipeleers D; Drucker DJ; Schuit F
    Diabetes; 1998 Apr; 47(4):646-52. PubMed ID: 9568699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, bioactivity and specificity of glucagon-like peptide-1 (7-37)/polymer conjugate to isolated rat islets.
    Kim S; Wan Kim S; Bae YH
    Biomaterials; 2005 Jun; 26(17):3597-606. PubMed ID: 15621250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired cyclic AMP response to stimuli in glucose-desensitized rat pancreatic islets.
    Laychock SG
    Mol Cell Endocrinol; 1995 Aug; 113(1):19-28. PubMed ID: 8674810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-1 structure, function and potential use for NIDDM.
    Gefel D; Barg Y; Zimlichman R
    Isr J Med Sci; 1997 Oct; 33(10):690-5. PubMed ID: 9397146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of glucagon-like peptide-1 (GLP-1) receptor and the effect of GLP-1-(7-36) amide on insulin release by pancreatic islets during rat ontogenic development.
    García-Flores M; Zueco JA; Alvarez E; Blázquez E
    Eur J Biochem; 2001 Feb; 268(3):514-20. PubMed ID: 11168389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.
    Gutniak MK; Juntti-Berggren L; Hellström PM; Guenifi A; Holst JJ; Efendic S
    Diabetes Care; 1996 Aug; 19(8):857-63. PubMed ID: 8842604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic exposure to GLP-1R agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo.
    Baggio LL; Kim JG; Drucker DJ
    Diabetes; 2004 Dec; 53 Suppl 3():S205-14. PubMed ID: 15561912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-like peptide 1 potentiates glucotoxicity-diminished insulin secretion via stimulation of cAMP-PKA signaling in INS-1E cells and mouse islets.
    Luo G; Kong X; Lu L; Xu X; Wang H; Ma X
    Int J Biochem Cell Biol; 2013 Feb; 45(2):483-90. PubMed ID: 23220045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide-1 stimulates insulin secretion but not phosphoinositide hydrolysis from islets desensitized by prior exposure to high glucose or the muscarinic agonist carbachol.
    Zawalich WS; Zawalich KC
    Metabolism; 1996 Feb; 45(2):273-8. PubMed ID: 8596502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.